New Age Alpha Advisors LLC Sells 13,425 Shares of Novanta Inc. $NOVT

Key Points

• New Age Alpha Advisors cut its Novanta stake by 64.8% in Q4, selling 13,425 shares and leaving it with 7,283 shares valued at about $867,000.
• Several analysts are mixed on the stock: Wall Street Zen downgraded Novanta to hold, while Robert W. Baird raised its price target to $173 and kept an outperform rating. The consensus analyst rating remains Hold with a $173 target.
• Novanta reported better-than-expected Q1 results, with EPS of $0.81 and revenue of $257.71 million, and the company raised guidance for fiscal 2026. Shares were trading near $161.51, close to their 52-week high.

New Age Alpha Advisors LLC decreased its holdings in shares of Novanta Inc. (NASDAQ:NOVT - Free Report) by 64.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,283 shares of the technology company's stock after selling 13,425 shares during the period. New Age Alpha Advisors LLC's holdings in Novanta were worth $867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in NOVT. Hantz Financial Services Inc. grew its stake in shares of Novanta by 376.3% during the 4th quarter. Hantz Financial Services Inc. now owns 905 shares of the technology company's stock valued at $108,000 after acquiring an additional 715 shares during the period. Coldstream Capital Management Inc. bought a new position in shares of Novanta during the 4th quarter valued at approximately $203,000. EverSource Wealth Advisors LLC grew its stake in shares of Novanta by 120.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company's stock valued at $51,000 after acquiring an additional 233 shares during the period. Legato Capital Management LLC grew its stake in shares of Novanta by 9.6% during the 4th quarter. Legato Capital Management LLC now owns 6,573 shares of the technology company's stock valued at $782,000 after acquiring an additional 575 shares during the period. Finally, Global Retirement Partners LLC grew its stake in shares of Novanta by 66,500.0% during the 4th quarter. Global Retirement Partners LLC now owns 666 shares of the technology company's stock valued at $79,000 after acquiring an additional 665 shares during the period. 98.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NOVT. Wall Street Zen downgraded Novanta from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Novanta in a report on Friday, April 17th. Finally, Robert W. Baird upped their target price on shares of Novanta from $144.00 to $173.00 and gave the stock an "outperform" rating in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Novanta currently has an average rating of "Hold" and a consensus target price of $173.00.

Insider Buying and Selling at Novanta

In other Novanta news, CEO Matthijs Glastra sold 7,500 shares of the business's stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $150.43, for a total value of $1,128,225.00. Following the sale, the chief executive officer owned 42,761 shares in the company, valued at $6,432,537.23. The trade was a 14.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert Buckley sold 9,957 shares of the business's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $116.77, for a total transaction of $1,162,678.89. Following the completion of the sale, the chief financial officer owned 96,616 shares in the company, valued at approximately $11,281,850.32. The trade was a 9.34% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 23,957 shares of company stock worth $3,136,229. Corporate insiders own 1.20% of the company's stock.

Novanta Trading Down 1.1%

Shares of Novanta stock opened at $161.51 on Thursday. The company has a market capitalization of $5.75 billion, a P/E ratio of 117.04 and a beta of 1.62. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.69 and a current ratio of 3.56. The company has a fifty day moving average of $132.44 and a 200 day moving average of $128.03. Novanta Inc. has a fifty-two week low of $98.27 and a fifty-two week high of $165.56.

Novanta (NASDAQ:NOVT - Get Free Report) last issued its earnings results on Monday, May 11th. The technology company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.03. The company had revenue of $257.71 million during the quarter, compared to the consensus estimate of $253.40 million. Novanta had a net margin of 5.35% and a return on equity of 12.06%. Novanta's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.74 EPS. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q2 2026 guidance at 0.810-0.860 EPS. On average, sell-side analysts anticipate that Novanta Inc. will post 3.59 earnings per share for the current fiscal year.

Novanta Company Profile

Novanta, Inc NASDAQ: NOVT is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta's product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta's Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.